Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Sparano

Showing results (191-200 of 293) with videos related to

Pageof 30
Sort By:
Journal of the National Cancer Institute|January 18, 2012
Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trialJoseph A Sparano, Molin Wang, Fengmin Zhao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2006
Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamideJoseph A Sparano, Stacy Moulder, Aslamuzzaman Kazi, et al.
Cancer Treatment Reviews|March 6, 2025
Current controversies in the use of Oncotype DX in early breast cancerPier Paolo M Berton Giachetti, Ambra Carnevale Schianca, Dario Trapani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancerBryan P Schneider, Fengmin Zhao, Molin Wang, et al.
Cancer|August 29, 2012
Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancerJoseph A Sparano, Molin Wang, Fengmin Zhao, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 11, 2018
Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075)Juan C Ramos, Joseph A Sparano, Michelle A Rudek, et al.
Breast Cancer Research and Treatment|June 18, 2017
A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104)Lori J Goldstein, Fengmin Zhao, Molin Wang, et al.
The American Journal of Cardiology|January 7, 1998
Angioplasty guidewire velocity: a new simple method to calculate absolute coronary blood velocity and flowC M Gibson, J T Dodge, M Goel, et al.
Haematologica|February 29, 2020
Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphomaJoseph A Sparano, Jeannette Y Lee, Lawrence D Kaplan, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 3, 2012
Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trialsLinda T Vahdat, Eva S Thomas, Henri H Roché, et al.
Pageof 30

Showing results (191-200 of 293) with videos related to

Sort By:
Pageof 30
Journal of the National Cancer Institute|January 18, 2012
Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trialJoseph A Sparano, Molin Wang, Fengmin Zhao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2006
Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamideJoseph A Sparano, Stacy Moulder, Aslamuzzaman Kazi, et al.
Cancer Treatment Reviews|March 6, 2025
Current controversies in the use of Oncotype DX in early breast cancerPier Paolo M Berton Giachetti, Ambra Carnevale Schianca, Dario Trapani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancerBryan P Schneider, Fengmin Zhao, Molin Wang, et al.
Cancer|August 29, 2012
Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancerJoseph A Sparano, Molin Wang, Fengmin Zhao, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 11, 2018
Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075)Juan C Ramos, Joseph A Sparano, Michelle A Rudek, et al.
Breast Cancer Research and Treatment|June 18, 2017
A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104)Lori J Goldstein, Fengmin Zhao, Molin Wang, et al.
The American Journal of Cardiology|January 7, 1998
Angioplasty guidewire velocity: a new simple method to calculate absolute coronary blood velocity and flowC M Gibson, J T Dodge, M Goel, et al.
Haematologica|February 29, 2020
Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphomaJoseph A Sparano, Jeannette Y Lee, Lawrence D Kaplan, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 3, 2012
Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trialsLinda T Vahdat, Eva S Thomas, Henri H Roché, et al.
Pageof 30